42,000 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Bought by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. bought a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 42,000 shares of the company's stock, valued at approximately $499,000. Hussman Strategic Advisors Inc. owned approximately 0.06% of Nurix Therapeutics at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. The Manufacturers Life Insurance Company lifted its holdings in shares of Nurix Therapeutics by 2.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company's stock valued at $585,000 after acquiring an additional 642 shares in the last quarter. Corebridge Financial Inc. grew its holdings in Nurix Therapeutics by 2.3% during the 4th quarter. Corebridge Financial Inc. now owns 34,907 shares of the company's stock worth $658,000 after acquiring an additional 770 shares in the last quarter. Kennedy Capital Management LLC boosted its holdings in shares of Nurix Therapeutics by 0.7% in the 4th quarter. Kennedy Capital Management LLC now owns 114,623 shares of the company's stock valued at $2,159,000 after buying an additional 785 shares during the period. Summit Investment Advisors Inc. boosted its holdings in shares of Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock valued at $138,000 after buying an additional 877 shares during the period. Finally, Arizona State Retirement System boosted its holdings in shares of Nurix Therapeutics by 8.7% in the 1st quarter. Arizona State Retirement System now owns 17,253 shares of the company's stock valued at $205,000 after buying an additional 1,385 shares during the period.

Nurix Therapeutics Stock Down 7.3%

Shares of NRIX traded down $0.88 during mid-day trading on Friday, hitting $11.21. 782,724 shares of the company's stock traded hands, compared to its average volume of 849,959. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56. The firm has a market capitalization of $857.00 million, a P/E ratio of -4.30 and a beta of 2.15. The business's 50-day moving average price is $11.47 and its 200-day moving average price is $13.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.27. The firm had revenue of $44,056 billion for the quarter, compared to the consensus estimate of $16.26 million. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%. Sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Oppenheimer set a $30.00 price target on shares of Nurix Therapeutics and gave the company an "outperform" rating in a report on Thursday, July 10th. Needham & Company LLC reissued a "buy" rating and issued a $27.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Morgan Stanley set a $16.00 target price on shares of Nurix Therapeutics and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. HC Wainwright cut their target price on shares of Nurix Therapeutics from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, July 14th. Finally, Wall Street Zen upgraded shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, Nurix Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $29.31.

Insider Activity

In related news, insider Gwenn Hansen sold 3,377 shares of the stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the sale, the insider owned 61,516 shares in the company, valued at approximately $707,434. This trade represents a 5.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Houte Hans Van sold 6,198 shares of the company's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total value of $70,223.34. Following the sale, the chief financial officer directly owned 33,724 shares in the company, valued at $382,092.92. This trade represents a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,013 shares of company stock valued at $137,096 in the last quarter. 7.40% of the stock is currently owned by company insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.